As of July 25, 2026, ten public companies collectively hold over 1 million bitcoin, with Strategy (formerly MicroStrategy) leading by a wide margin at 843,775 BTC. While Strategy's bitcoin holdings continue to grow, its stock has fallen 40% in 2026 due to capital management moves and market conditions. In contrast, bitcoin mining companies like Riot Platforms and Cleanspark have seen strong stock gains this year, benefiting from lower production costs and diversified AI infrastructure businesses. The divergence highlights investor preference for companies that mine bitcoin over those that only hold it, as miners control production costs and have more stable revenue streams. SpaceX also joined the list after its record IPO, holding 18,712 BTC, though its stock price has declined since debut. This split between miners and treasury holders is expected to shape bitcoin-linked stocks for the rest of 2026.
Gold prices fell more than 1% after US data showed initial jobless claims steady at 206,000, indicating a stable labor market. This stability suggests the Federal Reserve may feel confident to raise interest rates in its upcoming policy meeting. The ...
The Breakwave Tanker Shipping ETF (BWET) surged an extraordinary 3,000% in 2026, rising from $18.73 to $583.39 by September 10. This dramatic increase is linked to escalating hostilities between the U.S., Israel, and Iran, which have driven tanker ra...
Apnimed, Inc. is progressing its AD109 drug (Oxnimbi) for obstructive sleep apnea, showing strong Phase 3 results and a clear advantage over CPAP therapy. The company has a fully funded plan for commercialization, with an NDA under FDA review and a P...
Ethereum is trading around $2,470 following a strong 37% rally in late August, forming a bullish flag pattern that suggests a potential rise to $3,050 if it breaks current consolidation. The $3,050 target aligns with a historical resistance zone, mak...
Deutsche Bank acknowledged positive data from AstraZeneca's tozorakimab for chronic obstructive pulmonary disease (COPD), presented at the ERS conference, supporting the drug's commercial potential. Despite this, the bank maintained a 'sell' rating o...
